Newsletter

Subscribe to our newsletter to stay informed.

Newsletter Overlay EN
Salutation
* Mandatory fields
Policy

Board

The Interpharma Board determines the strategic direction of the association and represents the interests of research-based pharmaceutical companies in Switzerland.

Placeholder

Jörg-Michael Rupp 1

President

Director Pharma International – Roche

Placeholder

Julian Bertschinger 1

Vice-President

Head EMEA External Scientific Innovation – Johnson & Johnson

Placeholder

Myriam DeLeone 1

Vice-President

General Manager Switzerland – Amgen

Placeholder

Iris Zemzoum 1, 2

Vice-President

President Region Europe – Novartis

Placeholder

René P. Buholzer

Delegate of the Board

Interpharma

Placeholder

Jérome Garcin

General Manager for Switzerland and Austria – Bristol Myers Squibb

Placeholder

Thorsten Hein

Country Division Head, Pharmaceuticals – Bayer

Placeholder

Bairbre Hickie 1, 2

General Manager Switzerland – Takeda

Placeholder

Rea Lal

Country Lead of Pfizer Switzerland – Pfizer

Placeholder

Annette Luther 2

Head External Affairs Switzerland – Roche

Placeholder

Lauren McNamer

General Manager of Lilly Switzerland – Eli Lilly

Placeholder

Andrea Michael Meyer

Head Global Supply Chain Strategy & Excellence/VP – Sanofi

Placeholder

Michele Ravara

Managing Director for Switzerland – AbbVie

Placeholder

Florian Saur

Country President Switzerland – AstraZeneca

Placeholder

Patrick Schuler 2

Managing Director – Johnson & Johnson Innovative Medicine

Placeholder

David Traub

Managing Director Pharma Switzerland – Novartis

Placeholder

Anne Mette Wiis Vogelsang 2

CVP and General Manager Switzerland – Novo Nordisk

Legend:

1 Member of the Nomination and Membership Committee

2 Member of the Finance Board Committee